Black Diamond Therapeutics (BDTX)
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
📈 **POSITIVE** • Low confidence analysis (57%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (78%) **Content type:** Clinical